CA2185470A1 - Compositions and methods for vaccines comprising .alpha.-galactosyl epitopes - Google Patents

Compositions and methods for vaccines comprising .alpha.-galactosyl epitopes

Info

Publication number
CA2185470A1
CA2185470A1 CA002185470A CA2185470A CA2185470A1 CA 2185470 A1 CA2185470 A1 CA 2185470A1 CA 002185470 A CA002185470 A CA 002185470A CA 2185470 A CA2185470 A CA 2185470A CA 2185470 A1 CA2185470 A1 CA 2185470A1
Authority
CA
Canada
Prior art keywords
alpha
compositions
methods
vaccines
galactosyl epitopes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002185470A
Other languages
French (fr)
Other versions
CA2185470C (en
Inventor
Uri Galili
Patricia M. Repik
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Drexel University College of Medicine
Original Assignee
Uri Galili
Patricia M. Repik
Medical College Of Pennsylvania And Hahnemann University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Uri Galili, Patricia M. Repik, Medical College Of Pennsylvania And Hahnemann University filed Critical Uri Galili
Publication of CA2185470A1 publication Critical patent/CA2185470A1/en
Application granted granted Critical
Publication of CA2185470C publication Critical patent/CA2185470C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/193—Equine encephalomyelitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6087—Polysaccharides; Lipopolysaccharides [LPS]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/816—Viral vaccine for avian species, e.g. poultry or other birds

Abstract

The invention encompasses methods and compositions for inducing an immune response in an anti-Gal synthesizing animal including viral and tumor antigens manipulated to express .alpha.-galactosyl epitopes.
CA002185470A 1994-03-15 1995-03-13 Compositions and methods for vaccines comprising .alpha.-galactosyl epitopes Expired - Lifetime CA2185470C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US21320094A 1994-03-15 1994-03-15
US08/213,200 1994-03-15
PCT/US1995/003156 WO1995024924A1 (en) 1994-03-15 1995-03-13 COMPOSITIONS AND METHODS FOR VACCINES COMPRISING α-GALACTOSYL EPITOPES

Publications (2)

Publication Number Publication Date
CA2185470A1 true CA2185470A1 (en) 1995-09-21
CA2185470C CA2185470C (en) 2005-10-25

Family

ID=22794122

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002185470A Expired - Lifetime CA2185470C (en) 1994-03-15 1995-03-13 Compositions and methods for vaccines comprising .alpha.-galactosyl epitopes

Country Status (6)

Country Link
US (2) US5879675A (en)
EP (1) EP0754057B1 (en)
AU (1) AU2158995A (en)
CA (1) CA2185470C (en)
DE (1) DE69517683T2 (en)
WO (1) WO1995024924A1 (en)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5879675A (en) * 1994-03-15 1999-03-09 Medical College Of Pennsylvania And Hahnemann University Compositions and methods for vaccines comprising α-galactosyl epitopes
AU716818B2 (en) * 1995-10-24 2000-03-09 Sangstat Medical Corporation Anti alpha-galactosyl screening technique
DE19626614A1 (en) * 1996-07-02 1998-01-08 Immuno Ag Complex of antigen and cell component, vaccine composition containing the complex, pharmaceutical preparation and process for the preparation of the complex
US5869035A (en) * 1996-11-13 1999-02-09 Human Gene Therapy Research Institute Methods and compositions for inducing complement destruction of tissue
ATE427966T1 (en) * 1997-02-11 2009-04-15 Immunomedics Inc STIMULATION OF AN IMMUNE RESPONSE THROUGH ANTIBODIES LABELED WITH THE ALPHA-GALACTOSYLE PITOPOPE
CA2326618A1 (en) * 1998-04-15 1999-10-21 Baxter International Inc. Inhibition of xenoreactive antibodies
US6613330B1 (en) 1998-08-11 2003-09-02 Rush University Methods and compositions for preventing anti-Gal production in xenograft recipients
US7005126B1 (en) * 1999-06-08 2006-02-28 Human Gene Therapy Research Institute Method for tumor treatment using infusion of xenogeneic cells to induce hyperacute rejection and innocent bystander effect
US6818395B1 (en) * 1999-06-28 2004-11-16 California Institute Of Technology Methods and apparatus for analyzing polynucleotide sequences
US7033790B2 (en) 2001-04-03 2006-04-25 Curagen Corporation Proteins and nucleic acids encoding same
WO2003020039A1 (en) * 2001-08-28 2003-03-13 Rush-Presbyterian-St. Luke's Medical Center Immune tolerance to predetermined antigens
WO2003088995A2 (en) * 2002-04-22 2003-10-30 Recopharma Ab Mucin fusion polypeptide vaccines, compositions and methods of use thereof
US20050201993A1 (en) * 2002-10-09 2005-09-15 Link Charles J.Jr. Antitumor vaccination using allogeneic tumor cells expressing alpha (1,3)-galactosyltransferase
ES2341335T3 (en) * 2002-10-09 2010-06-18 Central Iowa Health System ANTI-TURMOR VACCINE USING ALLOGENIC TUMOR CELLS CODIFYING ALPHA (1,3) -GROACTOSIL TRNSFERSA.
WO2004069873A2 (en) * 2003-02-06 2004-08-19 Tripep Ab Antigen/antibody or ligand/receptor glycosylated specificity exchangers
US7820628B2 (en) * 2005-02-22 2010-10-26 University Of Massachusetts Medical School Tumor lesion regression and conversion in situ into autologous tumor vaccines by compositions that result in anti-Gal antibody binding
US7998486B2 (en) 2006-10-25 2011-08-16 Newlink Genetics Corporation Enhanced immunogenicity of tumor associated antigens by addition of alphaGal epitopes
EP2134361A4 (en) 2007-03-26 2010-09-22 Univ Massachusetts Medical Compositions and methods for increasing immunogenicity of glycoprotein vaccines
US8865178B2 (en) 2007-07-17 2014-10-21 University Of Massachusetts Compositions and methods for wound healing
US8084057B2 (en) * 2007-07-17 2011-12-27 University Of Massachusetts Compositions and methods for wound healing
US20090123494A1 (en) * 2007-07-31 2009-05-14 William Staplin Momlv-based pseudovirion packaging cell line
AU2009251328B2 (en) 2008-05-30 2014-10-02 Glycofi, Inc. Yeast strain for the production of proteins with terminal alpha-1,3-linked galactose
EP2499245B1 (en) * 2009-11-11 2016-09-14 Momenta Pharmaceuticals, Inc. Glycosyl transferase from chinese hamster and related methods
WO2012135313A1 (en) * 2011-03-28 2012-10-04 University Of Massachusetts Compositions and methods for detecting allergy to a-gal epitopes
US9861702B2 (en) 2012-10-22 2018-01-09 Wisconsin Alumni Research Foundation Lipid-conjugated rhamnose for immune system recruitment and oncotherapy
US10092586B2 (en) 2014-05-09 2018-10-09 Agalimmune Limited Glycolipid containing compositions for use in the treatment of tumors
US11471420B2 (en) * 2017-04-21 2022-10-18 Coastar Therapeutics Inc. Membrane lipid coated nanoparticles and method of use
EP3612169A4 (en) * 2017-04-21 2020-09-09 Coastar Therapeutics Inc. Membrane lipid coated nanoparticles and method of use

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4008317A (en) * 1975-12-29 1977-02-15 Recherche Et Industrie Therapeutiques (R.I.T.) Varicella-zoster virus vaccine and preparation thereof
US5879675A (en) * 1994-03-15 1999-03-09 Medical College Of Pennsylvania And Hahnemann University Compositions and methods for vaccines comprising α-galactosyl epitopes
US5871997A (en) * 1994-07-21 1999-02-16 Alexion Pharmaceuticals, Inc. Methods and compositions for protecting retroviral vector particles and producer cells from inactivation by complement via reduction of the expression or recognition of galactose alpha (1,3) galactosyl epitopes

Also Published As

Publication number Publication date
DE69517683T2 (en) 2001-06-07
EP0754057A4 (en) 1997-06-18
CA2185470C (en) 2005-10-25
EP0754057A1 (en) 1997-01-22
DE69517683D1 (en) 2000-08-03
US5879675A (en) 1999-03-09
WO1995024924A1 (en) 1995-09-21
AU2158995A (en) 1995-10-03
US6361775B1 (en) 2002-03-26
EP0754057B1 (en) 2000-06-28

Similar Documents

Publication Publication Date Title
CA2185470A1 (en) Compositions and methods for vaccines comprising .alpha.-galactosyl epitopes
AU709406C (en) Combined vaccines comprising hepatitis B surface antigen and other antigens
GB2210557B (en) Vaccine containing tumor antigens and refined detoxified endotoxin as an adjuvant.
GB9626483D0 (en) Helicobacter proteins and vaccines
CA2217178A1 (en) Vaccines containing a saponin and a sterol
ZA987591B (en) Vaccine.
CA2172507A1 (en) Methods and compositions for microencapsulation of antigens for use as vaccines
RU98100200A (en) HELICOBACTER PYLORI ANTIGENS AND VACCINE COMPOSITIONS
AU7980794A (en) Methods and compositions for microencapsulation of antigens for use as vaccines
ES500567A0 (en) PROCEDURE FOR PREPARING VACCINATION COMPLEXES BY REACTION OF RIBONOSAL RNA AND SPECIFIC ANTIGENS.
HUP0000318A3 (en) Tumor vaccine and process for the preparation thereof
DK1053017T3 (en) Vaccines comprising interleukin-12 and herpes simplex virus antigen
GB9309414D0 (en) Measles virus recombinant poxvirus vaccine
EP0487909A3 (en) Novel muramyldipeptide derivatives and influenza vaccine comprising the derivatives
AU7237391A (en) Carrier-bound recombinant protein, process for producing it and its use as an immunogen and vaccine
IL71953A (en) Malaria associated antigen,process for preparation thereof and vaccine comprising it
ZA9710205B (en) Bacterial antigens and vaccine compositions II.
CA2273922A1 (en) Novel saponin compositions and uses thereof
ITRM910385A0 (en) VACCINES USING ERYTHROCYTES AS VEHICLES OF ANTIGENS.
AU6761301A (en) Adjuvant composition comprising fha protein or fragment of fha protein in free form
EP0344211A4 (en) Monoclonal antibodies in vaccine formulations.
GB2238959B (en) Antigen and conjugates thereof for suppressing immune response
GB9309161D0 (en) Footrot antigens,vaccines and diagnostic assays
GB9021286D0 (en) Antigens and antibodies thereto their uses
NZ220611A (en) 30 residue influenza virus peptide, vaccines and antibodies

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry

Effective date: 20150313